Side-by-side comparison of AI visibility scores, market position, and capabilities
Bellevue WA premium commercial trucks (NASDAQ: PCAR) at $33.66B 2024 revenue, $4.16B earnings, 86th consecutive profitable year; Kenworth/Peterbilt 30.7% Class 8 market share, hydrogen FCEV deliveries 2025 competing with Daimler Freightliner.
PACCAR Inc. is a Bellevue, Washington-based premium commercial truck manufacturer — publicly traded on NASDAQ (NASDAQ: PCAR) as an S&P 500 Industrials component — designing and manufacturing heavy and medium-duty trucks under the Kenworth (North America), Peterbilt (North America), and DAF (Europe) brands through manufacturing facilities in the US, Netherlands, UK, Mexico, Brazil, and Australia, reporting $33.66 billion in 2024 revenue (second-best in company history), $4.16 billion in earnings, and its 86th consecutive year of net income. Founded in 1905 by William Pigott as a steel foundry and evolving through Seattle Car Manufacturing, Pacific Car and Foundry, and ultimately PACCAR, the company has built one of the most respected brands in long-haul trucking. In 2024, Kenworth and Peterbilt combined for 30.7% US and Canadian Class 8 heavy truck retail sales market share, with 185,300 vehicles delivered globally. PACCAR Parts (aftermarket parts distribution) set records with $6.67 billion in revenue and $1.71 billion in pretax income, demonstrating the high-margin recurring revenue stream from servicing the installed base of 1+ million PACCAR trucks. For 2025, PACCAR planned $700-800 million in capital projects and $460-500 million in R&D investment, targeting electric vehicle commercial production, hydrogen fuel cell truck delivery, and autonomous driving technology development. The Amplify Cell Technologies joint venture (with Daimler Truck and Accelera by Cummins, $2-3 billion investment) localizes battery cell manufacturing for electric Class 8 trucks in the US.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.